|Wednesday, 20 January 2010 05:33|
LOS ANGELES, CA-- BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has an exclusive interview with Robin L. Smith M.D., Chairman of the Board, Chief Executive Officer, of NeoStem (NYSE Amex: NBS).NeoStem is engaged in the business of developing stem cell therapies, pursuing anti-aging initiatives and is operating a network of adult stem cell collection centers that are focused on enabling people to donateand store stem cells for their personal use in times of future medical need.
"We think therapy is what is going to drive our business model;our company has grown over the last two and a half years from a single line to being a real therapeutics company," says Smith. "Our recently announced expansion into China is just that. We purchased a pharmaceutical company doing $60 million in revenue and we own 51% of that."
"It pays off right away because we are going from $80K in revenue to $60 million. So it pays off in that regard, and it's very profitable.To continue to enhance that piece of the business as China is going through their health care reform is important. We are very well poised to accept some of those revenues and grow in that area.But on top of that we can bring new innovative drugs and technologies, with our expertise, right into China. Right into that pipeline. So we think that is a tremendous opportunity today."
The complete interview is available now at BioMedReports.Com:
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com